Synairgen Share Discussion Threads

[royalalbert] 12/4/2020 12:04

Just wondering if you could ask him to clarify a few points, which you think Timbo would no more about.

Thankyou.

[spawny100] 12/4/2020 12:03

Agree DINGA given estimated cost of current shutdown is around £2.5 billion per day!

[141jaffa] 12/4/2020 11:59

oby_1... it was my understanding too that those most prone to severe disease /complications had amongst other things, low IFN levels for whatever, so SNG001 is hoped to "kick-start" the bodies natural mechanisms of defence. Thus also a primer treatment hopefully ??

[d1nga] 12/4/2020 11:56

£1000 per full length of treatment required is pennies in the grand scheme of things...

[royalalbert] 12/4/2020 11:56

Nobby are you in touch with Timbo.

[nobbygnome] 12/4/2020 11:54

>> oby1

Yet more encouraging data that interferon beta is the right drug in the right place. From personal experience I know that in vitro data is not always indicative of what happens in humans but is all you can do in the short term. This data certainly bodes well...

[nobbygnome] 12/4/2020 11:51

>> hsdeo

Per two week course as that is the likely length of a course of treatment since that isn't what the trial is assessing.

[likya123] 12/4/2020 11:50

From lse board....

'Germany does this for a living: we’re catching up’


Whilst not mentioning SNG by name, I reckon AZN chief, Sir Menelas has put in a good word with Government...




Lp160606

Today 11:34

Posts: 319

Price: 56.25

Great find that - thanks for posting. 

Almost certainly alluding to us. Penultimate paragraph.. 

'We are taking existing medicines we have today to treat Asthma, COPD, diabetes, heart failure and cancer, and we are seeing whether any of those could be useful for Covid-19 – and, further down the road but more likely to work – therapies that target Covid-a9 specifically, such as antivirals, antibodies’

Of course there are others but further confirmation we are all in the right place.

[oby_1] 12/4/2020 11:49

Interested to think what everyone (in particular Nobby) thinks to this article, it details that Covid-19 is particularly sensitive to IFN and demonstrates that dosing comparable to ours has a significant impact on viral replication. They hypothesis that one of the reasons for the huge difference in infection outcomes is down to an individuals ability to produce IFN



Some of the content is out of my league hence why I would value everyones input but the following two paragraphs read particularly well for me:

Our data clearly demonstrated that SARS-CoV-2 is highly sensitive to both IFN-a and IFN-b treatment in cultured cells.


Our data may also explain, at least in part, that approximately 80% of patients actually only developed mild symptoms and recovered (5). It is possible that many infected people developed IFN-a and IFN-b mediated innate immune response upon SARS-CoV-2 infection, which limits virus infection during initial stage. Later on, adaptive immune response, such as antibody production, may eventually help the recovery from the COVID-19 disease.

[nobbygnome] 12/4/2020 11:48

I believe the figure of £1000 came from the CEO but should not be taken as fact. Timbo would know more about this.....

And yes IMHO there will be a queue of Pharmas out the door looking to do a licensing deal or take them over. That means that SNG are in an extraordinarily strong position wrt to the terms of a deal. They could have done a deal now but took the bold step to do a fund raising and retain 100% ownership of the drug ahead of the trial result. I think that shows confidence in the result....

[hsdeo] 12/4/2020 11:48

Are people suggesting it is 1000 per person for the treatment and how long will the treatment last? If it was over more than a year then the cost is spread out I would assume, and so payments could also be spread out.

[jrlomax] 12/4/2020 11:43

Where has the figure of £1000 come from?

[wetdream] 12/4/2020 11:38

Assuming all’s good (ie ‘statistically significant’) with the trial, I can see tremendous pressure on SNG + their partner/s to keep the price down...
They’re gonna have to come up with some good cost-benefit data to justify £1000 to the ‘average’; man
Future cost savings (ie occupying an intensive care bed) down the line, however enormous, have less headline appeal than ‘Big Pharma ripping off the NHS’..blah,blah.
All imho.

[royalalbert] 12/4/2020 11:38

Morning Nobby, in your opinion do you think one of the big Pharmas will be running the rule over us, so to speak.

[nobbygnome] 12/4/2020 11:32

I should also add that the ordinal scale done on a daily basis which is the primary endpoint, will give loads of opportunity to analyse the data in multiple ways. Of course the benefit of this is that the likelihood of being able to find some endpoint which is statistically significant, is increased. The CEO confirmed this to me....

[nobbygnome] 12/4/2020 11:29

>> thwarnts

Well no-one knows for sure what will happen after a positive result. In theory the current study is just a pilot study which should then lead on to a larger study. However, if this trial shows a statistically significant result in a relatively difficult scenario because there are a relatively small number of patients, there will be massive pressure for an expedited approval on the back of this data. Normally that would go via the EMEA (the regulator for Europe) but I suspect in this case the individual countries would approve it. In the UK the MHRA expedited this trial so I think would approve it quickly. For the US the FDA can issue an EUA in such a situation and again I think there would be strong pressure for them to do that. When these results come out towards the end of May, the number of deaths in the US will still be high.

Now regulators are most worried about safety for obvious reasons and the benefit for SNG001 in this regard is that it has already been in loads of patients and has got a very clean safety record. So as long as nothing comes out of this study then safety will not hold back an approval.

[a.fewbob] 12/4/2020 11:10

Thanks Nobby.

[141jaffa] 12/4/2020 11:05

Recommended article posted yesterday by clinicians - hope it's helpful to people here, especially anyone expecting news quickly.

Synairgen are included and it's written and run by medics / researchers ( mostly UK). As a former healthcare provider myself, I think it's informative for investors here. For me, it's very reassuring that there have been no leaks /false promises / company ramps etc and I have confidence that the company are acting very responsibly here in keeping everything under wraps until the appropriate time. See what you think ?

[2nell] 12/4/2020 10:35

If interferon is given early enough, should it not stop any viral build up caused by covid19.

‘Early data from this double-blind, placebo-controlled trial have demonstrated that the antiviral responses in the lung (assessed using sputum biomarkers) are similar to those observed in the asthma trial, where we saw clinical benefit in lung function.’

[thwarnts] 12/4/2020 10:26

Hi Nobby,

I will be very disappointed if these trials aren't a major success.
If, and if they are a major success, where do we then go from there.
What would be the next phase in development ?
Do we need WHO approvement?
Sky's the limit?

[lmff1] 12/4/2020 09:55

Nobby. Thanks for the feedback.

[nobbygnome] 12/4/2020 09:55

Well we don't know that yet. The figure of about £1000 per course of treatment has been suggested but we will have to wait and see. And wrt other drugs nothing is approved yet so likewise we don't know.

[a.fewbob] 12/4/2020 09:50

Hi Nobby,

How does this compare to other treatments in terms of cost?

[nobbygnome] 12/4/2020 09:44

No treatment ever works for all patients and the potential market is massive so no real worries if other treatments appear. Plus SNG001 will be a generic treatment for all serious viral respiratory diseases in the future so is not limited to the current Covid 19 crisis. As long as it works this drug will be a massive money spinner. The company is currently valued at about £75 million allowing for the new shares coming next week which is clearly massively undervalued if the drug works.